Related Experiment Video

Updated: Jul 11, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

RAAS gene polymorphisms influence progression of pediatric hypertrophic cardiomyopathy

Beth D Kaufman1, Scott Auerbach, Sushma Reddy

  • 1Department of Pediatrics, Columbia University, New York, NY, 10032, USA.

Human Genetics
|September 14, 2007
PubMed

Insights

Genetic variations in the renin-angiotensin-aldosterone system (RAAS) are linked to worsening hypertrophic cardiomyopathy (HCM) in children. Specific RAAS gene polymorphisms predict increased septal thickness and outflow tract obstruction in pediatric HCM patients.

Area of Science:

  • Cardiology
  • Genetics
  • Pediatrics

Background:

  • Hypertrophic Cardiomyopathy (HCM) is a complex heart disease with variable progression.
  • Young age is a known risk factor for adverse outcomes in pediatric HCM.
  • The impact of renin-angiotensin-aldosterone system (RAAS) gene variations on HCM progression in children remains unclear.

Purpose of the Study:

  • To investigate the association between RAAS gene polymorphisms and the progression of left ventricular hypertrophy (LVH) in children with HCM.
  • To determine if specific RAAS genotypes influence the development of LV outflow tract (LVOT) obstruction.

Main Methods:

  • Prospective enrollment of 65 children with HCM.
  • Genotyping for five RAAS gene polymorphisms (AGT M235T, ACE DD, AGT M235T, AGTR1 1666 A/C, CYP11B2-344 C/T) associated with LVH.
  • Analysis of echocardiographic data, including LV mass index (LVMI) and interventricular septal thickness (IVST), at presentation and follow-up using linear regression models.

Main Results:

  • Children with two or more pro-LVH RAAS genotypes exhibited higher LVMI at presentation and follow-up compared to those with fewer.
  • A greater increase in IVST and LV outflow tract (LVOT) obstruction was observed in children with two or more pro-LVH genotypes.
  • Multivariate analysis confirmed that a higher number of pro-LVH genotypes independently predicted progressive septal hypertrophy and LVOT obstruction.

Conclusions:

  • Pro-LVH RAAS gene polymorphisms are associated with progressive septal hypertrophy and LVOT obstruction in pediatric HCM.
  • Identifying RAAS modifier genes may aid in risk stratification for children diagnosed with HCM.
  • Further research into genetic factors can personalize HCM management strategies.

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...